Lilly and Boehringer now have a Lantus Biosimilar available. Basaglar is available as a 100 Units/mL (U-100) strength in 3mL prefilled KwikPens in 5-count cartons.
Basaglar is a long-acting insulin with an amino acid sequence that is the same as Lantus, another insulin glargine 100 Units/mL product. It was initially approved by the Food and Drug Administration (FDA) in December 2015.
The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake—especially by skeletal muscle and fat—and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis. Cost saving should be at least 15% or more over Lantus insulin.